Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1026
Enova International
ENVA
$6.52B
| $14.7M | 0.02% |
990,300
+183,500
| +23% | +$2.6M |
|
1027
RCI Hospitality Holdings
RICK
$214M
| $14.7M | 0.02% |
616,700
+24,700
| +4% | +$486K |
|
|
ZPIN
1028
DELISTED
Zhaopin Limited
ZPIN
| $14.7M | 0.02% |
793,200
+279,300
| +54% | +$5.05M |
|
1029
ON Semiconductor
ON
$31.8B
| $14.7M | 0.02% |
1,046,196
-142,600
| -12% | -$2.14M |
|
|
ARNA
1030
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $14.7M | 0.02% |
869,366
+21,421
| +3% | +$294K |
|
1031
Acacia Research
ACTG
$455M
| $14.7M | 0.02% |
3,573,800
+68,200
| +2% | +$317K |
|
|
CBF
1032
DELISTED
Capital Bank Financial Corp. Class A Common Stock
CBF
| $14.6M | 0.02% |
382,344
+126,531
| +49% | +$5M |
|
1033
Willdan Group
WLDN
$1.29B
| $14.5M | 0.02% |
475,700
+2,984
| +0.6% | +$93.5K |
|
1034
Deluxe
DLX
$1.09B
| $14.5M | 0.02% |
209,800
+77,000
| +58% | +$5.37M |
|
1035
Valvoline
VVV
$4.25B
| $14.5M | 0.02% |
610,973
+529,220
| +647% | +$12.3M |
|
1036
QCR Holdings
QCRH
$1.73B
| $14.5M | 0.02% |
305,500
+6,500
| +2% | +$293K |
|
|
GBNK
1037
DELISTED
Guaranty Bancorp
GBNK
| $14.5M | 0.02% |
532,320
+112,700
| +27% | +$2.85M |
|
1038
Transocean
RIG
$6.39B
| $14.4M | 0.02% |
1,750,728
-1,352,600
| -44% | -$13.8M |
|
1039
Chemed
CHE
$7.02B
| $14.4M | 0.02% |
70,400
+50,200
| +249% | +$10M |
|
|
PRTK
1040
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $14.4M | 0.02% |
596,749
+182,236
| +44% | +$4.03M |
|
|
BKI
1041
DELISTED
Black Knight, Inc. Common Stock
BKI
| $14.3M | 0.02% |
350,200
+65,300
| +23% | +$2.58M |
|
|
AMAG
1042
DELISTED
AMAG Pharmaceuticals
AMAG
| $14.3M | 0.02% |
778,800
+12,800
| +2% | +$254K |
|
1043
First Busey Corp
BUSE
$2.58B
| $14.3M | 0.02% |
487,500
+72,600
| +17% | +$2.13M |
|
|
HAWK
1044
DELISTED
Blackhawk Network Holdings, Inc. Common Stock
HAWK
| $14.3M | 0.02% |
327,549
+114,496
| +54% | +$4.78M |
|
|
LDR
1045
DELISTED
Landauer Inc
LDR
| $14.3M | 0.02% |
273,000
-1,600
| -0.6% | -$82.4K |
|
|
HRG
1046
DELISTED
HRG Group, Inc.
HRG
| $14.3M | 0.02% |
806,007
-727,293
| -47% | -$13.7M |
|
1047
Pathward Financial
CASH
$1.78B
| $14.3M | 0.02% |
480,600
-17,400
| -3% | -$505K |
|
1048
Progress Software
PRGS
$1.79B
| $14.2M | 0.02% |
458,911
+310,900
| +210% | +$9.21M |
|
1049
Expeditors International
EXPD
$24B
| $14.2M | 0.02% |
250,800
-109,316
| -30% | -$6.02M |
|
1050
Embotelladora Andina Series B
AKO.B
$4.89B
| $14.1M | 0.02% |
553,800
+58,700
| +12% | +$1.45M |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.